AFT Pharmaceuticals Ltd. 2022 AR2
The report highlights AFT Pharmaceuticals' financial and operational performance for the fiscal year ended March 31, 2022, showcasing a 15.2% growth in operating revenue to $130.3 million and a 90.6% increase in operating profits to $20.4 million. The company expanded the global footprint of its flagship pain relief family, Maxigesic, with tablets sold in 46 countries and Maxigesic IV launched in new markets like South Korea. AFT also advanced its sustainability agenda by conducting its first detailed ESG materiality assessment, establishing a formal ESG framework, and preparing for future climate-related disclosures aligned with TCFD standards.
Company: AFT Pharmaceuticals Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2022
Type: AR2
Pages: 43
Back to company
AFT Pharmaceuticals Ltd.
Annual Report
The report highlights AFT Pharmaceuticals' financial and operational performance for the fiscal year ended March 31, 2022, showcasing a 15.2% growth in operating revenue to $130.3 million and a 90.6% increase in operating profits to $20.4 million. The company expanded the global footprint of its flagship pain relief family, Maxigesic, with tablets sold in 46 countries and Maxigesic IV launched in new markets like South Korea. AFT also advanced its sustainability agenda by conducting its first detailed ESG materiality assessment, establishing a formal ESG framework, and preparing for future climate-related disclosures aligned with TCFD standards.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees